ArticleJournal of neuro-oncology2025
Survival of nervous system tumors in a Colombian population cancer registry.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary tumors of the central nervous system (CNS) are rare, but they carry high morbidity and mortality. In Latin America, information on survival is limited. This study aimed to identify factors associated with survival of CNS tumors in a Colombian population.
methodsA retrospective cohort study was conducted with data from the Population Cancer Registry of the Metropolitan Area of Bucaramanga, including cases diagnosed between 2003 and 2017. Sociodemographic and clinical variables were analyzed. Survival was assessed using the Kaplan-Meier method and Cox proportional hazards models. Overall survival at 5 years and hazard ratios (HR) were estimated.
resultsA total of 1126 patients were included, with a median age at diagnosis of 55 years. 60.04% were malignant neoplasms. The most frequent histological subtypes were glioblastoma (27.9% of malignant tumors) and meningioma (80.3% of benign tumors). In total, 67.58% died, with 21.6 years of life lost per patient. Overall survival at 5 years was 57.5%. Malignant tumors had a survival rate of 39.6%. Glioblastoma had the worst prognosis (20.9% survival; HR 9.64; p < 0.001). Other significant predictors were: age ≥ 60 years (HR 1.92; p < 0.001), male sex (HR 1.37; p < 0.001), undifferentiated/anaplastic grade (HR 7.46; p < 0.001). No significant association was found between survival and socioeconomic status or type of insurance.
conclusionIn this cohort, the prognosis of CNS tumors was associated with age, sex, tumor behavior, histological subtype, location, and degree of differentiation. The premature mortality highlights the need to improve diagnostic accuracy and strengthen population registries with clinical and genetic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.